Luoheyi medical device enterprise has passed the acceptance and acceptance of the Henan Securities and Supervision Bureau, and plans to pierce the Bei Stock Exchange

[Dahecai Cube News] On the evening of June 24, Henan Shuguang Huikang Biotechnology Co., Ltd. (hereinafter referred to as Huizhikang) announced that it had received the "About Northeast Securities Co., Ltd. Counseling Counseling Corporation of the Henan Securities Regulatory Bureau "Completion letter of work for work", the company passed the counseling acceptance of Henan Securities and Supervision Bureau under the guidance of Northeast Securities of Counseling Institutions.

Hui Zhikang is located in Yuanhui District, Luohe City. It mainly uses one -time medical equipment such as inflammatory infusion, injection, and syringes. The company is listed on the New Third Board and is currently on the innovation layer.

In August 2021, Hui Zhikang was identified by the "Special New Small and Small Enterprises" of the Henan Provincial Department of Industry and Information Technology. In October 2021, Hui Zhikang obtained a "high -tech enterprise" certificate jointly issued by the Henan Provincial Department of Science and Technology, Henan Provincial Department of Finance, and the State Administration of Taxation Henan Provincial Taxation Bureau.

Financial data shows that the net profit attributable to shareholders of the listed company in 2020 and 2021 (the calculation basis for deducting the low before and after the deduction of non -recurring profit or loss) was 36.6628 million yuan and 43.77 million yuan, respectively. The average weighted average was The net assets yield (low calculation of net profit attributable to the owner of the parent company after deducting non -recurring profit or loss) is 13.06%and 13.49%, respectively, which is in line with Article 2.1.3 of the Listing Rules. Financial conditions.

Responsible editor: Chen Yuyao | Review: Li Zhen | Director: Wan Junwei

- END -